Hospital
Albert Einstein Medical Center
Albert Einstein Medical Center was paid $81.13M by Medicaid between Aug 2018 and Dec 2024, across 445 billing codes. Its largest line is 99283, emergency room visit (moderate) — 15% of everything it billed.
33Billing provider infoALBERT EINSTEIN MEDICAL CENTER
PHILA, PA 19141
PHILA, PA 19141
33aNPI1902805245assigned 07/19/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$81.13M
24GClaims1,034,137
24DCodes billed445
24AFirst – last monthAug 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#2 of 154
Median peer was paid$2.82M
This provider vs. median29×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 468 | $200K | |
| 2019 | 21,483 | $1.57M | |
| 2020 | 151,830 | $7.57M | |
| 2021 | 403,053 | $27.08M | |
| 2022 | 156,399 | $15.78M | |
| 2023 | 151,565 | $16.15M | |
| 2024incomplete | 149,339 | $12.77M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 57,007 | 54,739 | $11.89M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 56,139 | 53,520 | $10.80M |
| G0378 | Hospital observation service, per hour | 13% | 8,160 | 6,661 | $10.59M |
| H2011 | Crisis intervention service, per 15 minutes | 10% | 16,823 | 13,979 | $8.42M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.8% | 23,011 | 21,979 | $3.92M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 3.8% | 20,567 | 18,817 | $3.07M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.9% | 30,848 | 28,997 | $2.37M |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 2.4% | 1,396 | 1,306 | $1.93M |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 2.3% | 1,177 | 1,147 | $1.84M |
| 90837 | Psychotherapy session, about an hourPsychotherapy, 53 minutes with patient | 1.7% | 14,095 | 6,118 | $1.37M |
| 62323 | 1.4% | 1,764 | 1,701 | $1.17M | |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 1.4% | 18,711 | 15,209 | $1.16M |
433 more codes
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.4% | 1,167 | $1.10M |
| 99213 | Doctor's office visit, returning patient (routine) | 1.2% | 20,992 | $992K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.2% | 6,687 | $978K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.2% | 18,776 | $971K |
| 99215 | Doctor's office visit, returning patient (complex) | 1.0% | 8,320 | $843K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 6,294 | $752K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 645 | $584K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 567 | $564K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 5,966 | $558K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 4,098 | $539K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,291 | $510K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 10,144 | $500K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,325 | $480K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 12,403 | $477K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 3,950 | $454K |
| 19318 | <1% | 292 | $452K | |
| H0034 | Medication training and support, per 15 minutes | <1% | 5,069 | $425K |
| S5000 | Prescription drug, generic | <1% | 67,048 | $405K |
| 99235 | <1% | 491 | $405K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 3,263 | $359K |
| 59025 | Fetal non-stress test | <1% | 9,461 | $274K |
| 76818 | <1% | 3,629 | $273K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 5,737 | $263K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 3,909 | $261K |
| 76801 | <1% | 4,305 | $233K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 4,435 | $230K |
| 76813 | <1% | 3,333 | $193K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,910 | $184K |
| 95811 | <1% | 315 | $177K | |
| 64483 | <1% | 248 | $174K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 503 | $170K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,334 | $163K |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | <1% | 48 | $146K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,108 | $144K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,483 | $142K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 13,026 | $141K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 619 | $136K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 392 | $133K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 5,282 | $131K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 461 | $130K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 505 | $118K |
| 77066 | Tomosynthesis, mammo | <1% | 1,211 | $117K |
| 19083 | <1% | 194 | $117K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 45,227 | $115K |
| 43235 | <1% | 129 | $115K | |
| 64721 | <1% | 84 | $112K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 602 | $105K |
| 20610 | <1% | 370 | $103K | |
| 73564 | <1% | 4,267 | $101K | |
| 95886 | <1% | 2,313 | $100K | |
| 80053 | Comprehensive metabolic panel | <1% | 15,283 | $99K |
| 76830 | Ultrasound, transvaginal | <1% | 1,887 | $96K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 680 | $93K |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | <1% | 31 | $91K |
| 73562 | <1% | 4,593 | $90K | |
| 76820 | <1% | 2,349 | $84K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,184 | $84K |
| 77065 | Tomosynthesis, mammo | <1% | 1,174 | $81K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 301 | $79K |
| 76642 | <1% | 1,443 | $79K | |
| 73610 | <1% | 3,968 | $79K | |
| 72110 | <1% | 2,514 | $77K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,679 | $77K |
| Q3014 | Telehealth originating site facility fee | <1% | 5,242 | $77K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 687 | $76K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 20,929 | $75K |
| 49083 | <1% | 267 | $74K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 23,403 | $74K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 410 | $72K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,142 | $70K |
| 93017 | <1% | 1,135 | $69K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 19,718 | $68K |
| 72141 | <1% | 313 | $68K | |
| 81000 | <1% | 4,264 | $67K | |
| 73221 | <1% | 254 | $66K | |
| 58661 | <1% | 62 | $66K | |
| 71250 | <1% | 910 | $62K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 141 | $61K |
| 0011A | <1% | 1,312 | $60K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,964 | $60K |
| 0012A | <1% | 1,178 | $59K | |
| 99219 | <1% | 239 | $58K | |
| 77412 | <1% | 1,009 | $55K | |
| G0008 | Administration of influenza virus vaccine | <1% | 4,076 | $51K |
| 99201 | <1% | 802 | $49K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 447 | $49K |
| 73630 | <1% | 3,468 | $49K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 913 | $49K |
| 0001A | <1% | 939 | $48K | |
| 73130 | <1% | 3,382 | $48K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,569 | $47K |
| 93970 | <1% | 524 | $46K | |
| 76536 | <1% | 883 | $46K | |
| 97602 | <1% | 176 | $45K | |
| 73030 | <1% | 2,591 | $43K | |
| 74183 | <1% | 96 | $42K | |
| 0002A | <1% | 799 | $42K | |
| 11982 | <1% | 45 | $42K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,748 | $41K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 7,130 | $41K |
| 58300 | <1% | 61 | $41K | |
| 99205 | Prolong outpt/office vis | <1% | 283 | $41K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,092 | $41K |
| 58301 | <1% | 39 | $37K | |
| 95911 | <1% | 484 | $35K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 604 | $35K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 910 | $34K |
| 73502 | <1% | 1,520 | $34K | |
| 83735 | <1% | 25,278 | $34K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,767 | $33K |
| 93971 | <1% | 708 | $32K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 694 | $31K |
| 96417 | <1% | 402 | $31K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 241 | $31K |
| 80197 | <1% | 3,044 | $30K | |
| 85027 | <1% | 8,829 | $30K | |
| 71271 | <1% | 365 | $28K | |
| 58558 | <1% | 28 | $27K | |
| 77080 | <1% | 473 | $27K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 346 | $27K |
| 99243 | <1% | 365 | $27K | |
| 95806 | <1% | 273 | $26K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 605 | $26K |
| 93975 | <1% | 373 | $25K | |
| 84100 | <1% | 23,555 | $25K | |
| 95913 | <1% | 252 | $25K | |
| 77062 | <1% | 865 | $24K | |
| 99245 | <1% | 151 | $24K | |
| 90686 | <1% | 3,174 | $23K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 1,511 | $22K |
| 73110 | <1% | 1,644 | $22K | |
| C1769 | Guide wire | <1% | 934 | $22K |
| 73523 | <1% | 517 | $22K | |
| 77336 | <1% | 482 | $22K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,716 | $22K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 495 | $21K |
| 96367 | <1% | 916 | $21K | |
| 94729 | <1% | 599 | $20K | |
| 93923 | <1% | 365 | $20K | |
| 59430 | <1% | 359 | $20K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 144 | $19K |
| 72100 | <1% | 959 | $19K | |
| 47562 | <1% | 12 | $19K | |
| 77061 | <1% | 751 | $19K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 719 | $17K |
| 94726 | <1% | 569 | $17K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,643 | $17K |
| 70496 | <1% | 366 | $17K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,199 | $17K |
| 93356 | <1% | 657 | $17K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,794 | $17K |
| 72050 | <1% | 495 | $17K | |
| 73560 | <1% | 1,236 | $17K | |
| 82248 | <1% | 7,808 | $17K | |
| 99242 | <1% | 235 | $16K | |
| 76775 | <1% | 379 | $16K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 2,678 | $15K |
| 76770 | <1% | 339 | $15K | |
| 94060 | <1% | 708 | $15K | |
| 91200 | <1% | 376 | $15K | |
| 96415 | <1% | 446 | $15K | |
| 64493 | <1% | 35 | $14K | |
| 77334 | <1% | 95 | $14K | |
| G0296 | Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) | <1% | 349 | $14K |
| 82803 | <1% | 2,601 | $14K | |
| 82962 | <1% | 11,196 | $13K | |
| 84702 | <1% | 1,542 | $13K | |
| 90732 | <1% | 393 | $13K | |
| 90715 | <1% | 1,491 | $12K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 133 | $12K |
| 81025 | <1% | 11,840 | $12K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 958 | $12K |
| 93880 | <1% | 130 | $11K | |
| 0013A | <1% | 245 | $11K | |
| 70486 | <1% | 358 | $11K | |
| 26055 | <1% | 19 | $11K | |
| 74174 | <1% | 127 | $11K | |
| 95910 | <1% | 162 | $10K | |
| 70498 | <1% | 320 | $10K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,077 | $10K |
| 92558 | <1% | 50 | $10K | |
| 72040 | <1% | 510 | $9K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 76 | $9K |
| 83880 | <1% | 1,563 | $9K | |
| 73590 | <1% | 717 | $9K | |
| 99407 | <1% | 374 | $9K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 770 | $8K |
| 87631 | <1% | 273 | $8K | |
| 74178 | <1% | 43 | $8K | |
| 64494 | <1% | 42 | $8K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,288 | $8K |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 78 | $8K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,235 | $7K |
| 72114 | <1% | 275 | $7K | |
| 96376 | <1% | 1,059 | $7K | |
| 76376 | <1% | 185 | $7K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,871 | $7K |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 953 | $7K |
| 90656 | <1% | 559 | $7K | |
| 84484 | <1% | 7,296 | $7K | |
| 90714 | <1% | 1,167 | $7K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 136 | $7K |
| 94618 | <1% | 374 | $7K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,485 | $7K |
| 72070 | <1% | 288 | $6K | |
| 86832 | <1% | 73 | $6K | |
| 86833 | <1% | 73 | $6K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 276 | $6K |
| 93226 | <1% | 125 | $5K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 675 | $5K |
| 93350 | <1% | 81 | $5K | |
| 76821 | <1% | 85 | $5K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 444 | $5K |
| G0009 | Administration of pneumococcal vaccine | <1% | 474 | $5K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,827 | $5K |
| 76870 | <1% | 131 | $5K | |
| 0003A | <1% | 113 | $5K | |
| 73552 | <1% | 350 | $5K | |
| 81003 | <1% | 6,057 | $5K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 486 | $5K |
| 72197 | <1% | 12 | $5K | |
| 88341 | <1% | 80 | $5K | |
| 99152 | <1% | 280 | $4K | |
| 96040 | <1% | 176 | $4K | |
| 85610 | <1% | 3,977 | $4K | |
| 29580 | <1% | 23 | $4K | |
| 86850 | <1% | 1,892 | $4K | |
| 92250 | <1% | 78 | $4K | |
| 96402 | <1% | 144 | $4K | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 483 | $4K |
| 73080 | <1% | 389 | $4K | |
| 74018 | <1% | 267 | $4K | |
| 93925 | <1% | 64 | $4K | |
| 96127 | <1% | 49 | $4K | |
| 76519 | <1% | 113 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,283 | $4K |
| 87497 | <1% | 114 | $4K | |
| 85730 | <1% | 2,596 | $4K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,108 | $4K |
| 73090 | <1% | 350 | $4K | |
| 93225 | <1% | 143 | $4K | |
| 86900 | <1% | 2,263 | $4K | |
| 73140 | <1% | 322 | $4K | |
| 93978 | <1% | 85 | $4K | |
| J7297 | Levonorgestrel-releasing intrauterine contraceptive system (liletta), 52 mg | <1% | 13 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,544 | $3K |
| 77300 | <1% | 30 | $3K | |
| 80061 | Lipid panel | <1% | 824 | $3K |
| 80320 | <1% | 810 | $3K | |
| 70491 | <1% | 54 | $3K | |
| 88342 | <1% | 682 | $3K | |
| 83605 | <1% | 2,940 | $3K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,447 | $3K |
| 80305 | <1% | 316 | $3K | |
| 87070 | <1% | 915 | $3K | |
| 82247 | <1% | 400 | $3K | |
| 97162 | <1% | 227 | $3K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 210 | $3K |
| 78306 | <1% | 42 | $3K | |
| 86901 | <1% | 2,101 | $3K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 37 | $2K |
| 81001 | <1% | 4,493 | $2K | |
| 36430 | <1% | 69 | $2K | |
| 97161 | <1% | 231 | $2K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 335 | $2K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 246 | $2K |
| 83690 | <1% | 3,662 | $2K | |
| C1729 | Catheter, drainage | <1% | 73 | $2K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 597 | $2K |
| 10060 | <1% | 78 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,563 | $2K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 982 | $2K |
| 89051 | <1% | 409 | $2K | |
| 73060 | <1% | 223 | $2K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 158 | $2K |
| A4648 | Tissue marker, implantable, any type, each | <1% | 17 | $2K |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 142 | $2K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,413 | $2K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 469 | $2K |
| 86803 | <1% | 469 | $2K | |
| 72170 | <1% | 333 | $2K | |
| 87205 | <1% | 674 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,128 | $2K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 1,147 | $2K |
| 87340 | <1% | 304 | $2K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 448 | $2K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 251 | $2K |
| 95812 | <1% | 27 | $2K | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,265 | $2K |
| 88173 | <1% | 16 | $2K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 15 | $2K |
| 81002 | <1% | 422 | $1K | |
| 77002 | <1% | 50 | $1K | |
| 73600 | <1% | 81 | $1K | |
| 82570 | <1% | 448 | $1K | |
| 72081 | <1% | 39 | $1K | |
| 74170 | <1% | 12 | $1K | |
| 77280 | <1% | 31 | $1K | |
| 96411 | <1% | 21 | $1K | |
| 87522 | Neg quan hep c or qual rna | <1% | 64 | $1K |
| 86593 | <1% | 540 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 6,407 | $1K |
| 76882 | <1% | 65 | $1K | |
| 82728 | <1% | 358 | $927.32 | |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 37 | $888.28 |
| G0010 | Administration of hepatitis b vaccine | <1% | 56 | $885.23 |
| 90746 | <1% | 138 | $818.91 | |
| 90734 | <1% | 68 | $801.20 | |
| 86706 | <1% | 184 | $776.74 | |
| A4212 | Non-coring needle or stylet with or without catheter | <1% | 103 | $765.82 |
| 97166 | <1% | 34 | $743.49 | |
| 86592 | <1% | 543 | $739.90 | |
| 84156 | <1% | 422 | $716.40 | |
| 87186 | <1% | 504 | $687.63 | |
| 73000 | <1% | 45 | $682.53 | |
| 97010 | <1% | 619 | $681.79 | |
| 82607 | <1% | 311 | $668.70 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,483 | $663.58 |
| 95909 | <1% | 15 | $624.42 | |
| 83540 | <1% | 316 | $621.21 | |
| 80329 | <1% | 237 | $608.31 | |
| 93280 | <1% | 52 | $588.85 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 91 | $581.27 |
| 36416 | <1% | 143 | $549.46 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,197 | $542.89 |
| 97116 | <1% | 366 | $489.14 | |
| 86580 | <1% | 119 | $480.17 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 687 | $474.97 |
| 29125 | <1% | 114 | $468.42 | |
| 90662 | <1% | 47 | $463.40 | |
| 76937 | <1% | 121 | $445.17 | |
| 82746 | <1% | 227 | $430.92 | |
| 77331 | <1% | 20 | $428.30 | |
| J3490 | Unclassified drugs | <1% | 2,562 | $399.83 |
| 76857 | <1% | 14 | $398.90 | |
| 74420 | <1% | 27 | $393.99 | |
| 73100 | <1% | 28 | $382.51 | |
| 72052 | <1% | 13 | $373.28 | |
| 85384 | <1% | 110 | $356.53 | |
| 88307 | <1% | 149 | $328.95 | |
| 84703 | <1% | 349 | $320.08 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,393 | $319.74 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 154 | $314.78 |
| 87081 | <1% | 224 | $308.97 | |
| 87040 | <1% | 335 | $304.72 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 263 | $297.79 |
| 83550 | <1% | 241 | $291.52 | |
| 92083 | <1% | 12 | $287.02 | |
| 86704 | <1% | 31 | $282.07 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 829 | $276.60 |
| 99417 | Prolong home eval add 15m | <1% | 28 | $274.42 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 105 | $272.93 |
| 71101 | <1% | 27 | $269.72 | |
| 92133 | <1% | 13 | $264.92 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,540 | $242.18 |
| 73070 | <1% | 31 | $240.16 | |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 12 | $239.25 |
| 77417 | <1% | 27 | $224.98 | |
| 84550 | <1% | 84 | $223.81 | |
| 82550 | <1% | 372 | $216.45 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 315 | $215.92 |
| S0028 | Injection, famotidine, 20 mg | <1% | 1,117 | $206.39 |
| 93282 | <1% | 12 | $179.15 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 439 | $174.61 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,330 | $171.08 |
| 83615 | <1% | 88 | $170.97 | |
| 92228 | <1% | 17 | $165.35 | |
| 87102 | <1% | 30 | $162.50 | |
| 84439 | <1% | 212 | $158.75 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,524 | $150.25 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,260 | $146.77 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,732 | $142.39 |
| 88304 | <1% | 266 | $138.17 | |
| 12001 | <1% | 77 | $137.85 | |
| 99406 | <1% | 13 | $126.83 | |
| 82043 | <1% | 31 | $125.19 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 129 | $124.93 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 32 | $123.42 |
| 73620 | <1% | 17 | $115.34 | |
| 85007 | <1% | 33 | $110.00 | |
| 82150 | <1% | 18 | $103.73 | |
| 85652 | <1% | 298 | $103.14 | |
| 86140 | <1% | 312 | $99.02 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,947 | $98.93 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 41 | $98.80 |
| 87116 | <1% | 16 | $98.30 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 80 | $91.58 |
| 77001 | <1% | 15 | $86.20 | |
| 80164 | <1% | 35 | $74.88 | |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | <1% | 33 | $73.96 |
| 85045 | <1% | 75 | $63.97 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,189 | $44.51 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,438 | $43.53 |
| 87206 | <1% | 16 | $39.31 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,045 | $37.18 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,390 | $26.00 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 201 | $20.76 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 263 | $17.63 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,772 | $16.04 |
| 82436 | <1% | 20 | $12.56 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 1,104 | $12.48 |
| 84300 | <1% | 20 | $12.16 | |
| 84133 | <1% | 20 | $10.74 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 40 | $5.68 |
| 82010 | <1% | 64 | $5.00 | |
| 84560 | <1% | 19 | $4.50 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 464 | $4.37 |
| 83935 | <1% | 19 | $3.00 | |
| 83014 | <1% | 28 | $1.38 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 330 | $0.00 |
| J1750 | Injection, iron dextran, 50 mg | 0% | 78 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 63 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 86 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 89 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 99 | $0.00 |
| 88302 | 0% | 17 | $0.00 | |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | 0% | 14 | $0.00 |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 0% | 15 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 273 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 49 | $0.00 |
| 84540 | 0% | 18 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 863 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 46 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 37 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 39 | $0.00 |
| 86780 | 0% | 119 | $0.00 | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 0% | 36 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 127 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 51 | $0.00 |
| 12002 | 0% | 28 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 22 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 16 | $0.00 |
| 88300 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRUSSO, SAMUEL (CORP DIRECTOR OF FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Albert Einstein Medical Center | Phila, PA | $14.46M |
| Albert Einstein Medical Center | Phila, PA | $5K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.